While RAPT Therapeutics Inc has overperformed by 10.00%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RAPT fell by -81.00%, with highs and lows ranging from $27.35 to $1.64, whereas the simple moving average fell by -68.27% in the last 200 days.
On May 14, 2024, Wolfe Research Downgraded RAPT Therapeutics Inc (NASDAQ: RAPT) to Peer Perform. A report published by Guggenheim on May 10, 2024, Downgraded its rating to ‘Neutral’ for RAPT. Barclays also Downgraded RAPT shares as ‘Equal Weight’, setting a target price of $4 on the company’s shares in a report dated May 10, 2024. UBS February 22, 2024d the rating to Neutral on February 22, 2024, and set its price target from $61 to $10. Leerink Partners February 21, 2024d its ‘Outperform’ rating to ‘Market Perform’ for RAPT, as published in its report on February 21, 2024. JP Morgan’s report from February 21, 2024 suggests a price prediction of $15 for RAPT shares, giving the stock a ‘Neutral’ rating. H.C. Wainwright also rated the stock as ‘Neutral’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of RAPT Therapeutics Inc (RAPT)
In order to gain a clear picture of RAPT Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -77.97% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 8.14, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 260.47K can be a very valuable indicator of volatility for RAPT stock. On a monthly basis, the volatility of the stock is set at 11.17%, whereas on a weekly basis, it is put at 13.47%, with a gain of 27.91% over the past seven days. Furthermore, long-term investors anticipate a median target price of $8.00, showing growth from the present price of $2.20, which can serve as yet another indication of whether RAPT is worth investing in or should be passed over.
How Do You Analyze RAPT Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 11.19%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 82.24% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
RAPT shares are owned by institutional investors to the tune of 82.24% at present.
